Arcadia Biosciences Inc (RKDA)

Arcadia Biosciences, Inc. is a NASDAQ-listed common stock company focused on plant-based food and beverage products in the United States. The company also develops crop improvement technologies, with an emphasis on wheat, aimed at improving field performance and enhancing the value of crops as food ingredients. Its product lineup has included GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring. Founded in 2002 and headquartered in Dallas, Texas, Arcadia Biosciences operates across both agricultural innovation and consumer food and beverage categories.


Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-RKDA
$0.22
31.0% Upside
Undervalued
Not available
Not available
Weak
0.0%
0.6x
0.1x
408.12 K
-3.776 M
0.0%
90.0%
-158.9
22.8%
Valuation • Fair Value

Arcadia Biosciences Inc (NASDAQ-RKDA) Fair Value by Valuation Model

Review the available estimates for Arcadia Biosciences Inc (NASDAQ-RKDA), including Comps Fair Value.

Primary Valuation Read

Fair Value

$0.22

Estimated upside of 31.0% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Comps Fair Value

$0.22

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 3 available valuation references for Arcadia Biosciences Inc (NASDAQ-RKDA) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Arcadia Biosciences Inc (NASDAQ-RKDA)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

4.746 M

Current operating scale indicator.

Revenue Forecast

7.7 M

Forward revenue estimate.

EBITDA

-3.792 M

Current operating profitability reference.

EBITDA Forecast

-3.748 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Arcadia Biosciences Inc (NASDAQ-RKDA) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Arcadia Biosciences Inc (NASDAQ-RKDA)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

3

Weak quality score that deserves closer review.

Beneish M-Score

-9.79

No elevated caution signal from this screen.

Altman Z-Score

-158.9

Lower score that deserves closer risk review.

FCF / Net Income

22.8%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Arcadia Biosciences Inc (NASDAQ-RKDA). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Dividend Profile for Arcadia Biosciences Inc (NASDAQ-RKDA)

Review the dividend metrics currently supported by the latest data.

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

The latest data indicates no current dividend yield for Arcadia Biosciences Inc (NASDAQ-RKDA). No upcoming dividend amount or event date is currently available.

Stock Forecast • Technical Outlook

Arcadia Biosciences Inc (NASDAQ-RKDA) Stock Forecast & Technical Outlook

Review Arcadia Biosciences Inc (NASDAQ-RKDA) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Arcadia Biosciences Inc (NASDAQ-RKDA) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Arcadia Biosciences Inc (NASDAQ-RKDA) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Neutral

The daily technical read for Arcadia Biosciences Inc (NASDAQ-RKDA) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Arcadia Biosciences Inc (NASDAQ-RKDA) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Arcadia Biosciences Inc (NASDAQ-RKDA) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Arcadia Biosciences Inc (NASDAQ-RKDA)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Arcadia Biosciences Inc (NASDAQ-RKDA) has a Strong Buy consensus, with 1 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 1
Hold 0
Sell 0
FAQ • Fast Investor Answers

Arcadia Biosciences Inc (NASDAQ-RKDA) Stock FAQ

Data-supported answers about Arcadia Biosciences Inc (NASDAQ-RKDA), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$0.22
Estimated upside 31.0%
Valuation Rating
Undervalued
Estimated upside of 31.0%
Financial Health
Weak
Current financial-health read

The current fair value estimate for Arcadia Biosciences Inc (NASDAQ-RKDA) is $0.22. This implies an estimated upside of 31.0% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 31.0% versus the current market price.

The current financial health read for Arcadia Biosciences Inc (NASDAQ-RKDA) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The latest available data indicates no current dividend yield for Arcadia Biosciences Inc (NASDAQ-RKDA).

The current market capitalization listed for Arcadia Biosciences Inc is 408.12 K.

The current enterprise value listed for Arcadia Biosciences Inc is -3.776 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Arcadia Biosciences Inc is NASDAQ-RKDA, and the stock is listed on NASDAQ.

Arcadia Biosciences Inc (NASDAQ-RKDA) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Arcadia Biosciences Inc is 0.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Arcadia Biosciences Inc is 90.0%. Free float helps investors understand how much of the share base is available for public trading.